Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450183 · ClinicalTrials.gov registry record · Phase 2
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
A Phase 2 study, sponsored by Henry Ford Health System.
- Not yet
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT07450183 is a Phase 2 study that has not yet begun recruiting, run by Henry Ford Health System. The registered enrollment target is 33 participants.
The verdict
NCT07450183, a Phase 2 study, has not yet begun recruiting, sponsored by Henry Ford Health System.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the amount of residual tumor in the resected tissue after 3 cycles of cemiplimab. After surgery, all patients will receive additional 10 cycles of cemiplimab and the treating oncologist will decide on the need of administering chemotherapy prior to that.
Interventions
- DRUG Cemiplimab
- DRUG Adjuvant chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07450183
The ClinicalTrials.gov registry entry for NCT07450183 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT07450183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07450183 about?
NCT07450183 is a clinical study titled "Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1". This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by ...
What is the current status of trial NCT07450183?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2026-06-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07450183?
The interventions under investigation include: Cemiplimab (DRUG), Adjuvant chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07450183?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.